Corrigendum


Lijun Song a, Martijn D.P. Risseeuw a, Matheus Froeyen b, Izet Karalic a, Jan Goeman c, Davie Cappoen d, Johan Van der Eycken c, Paul Cos d, Hélène Munier-Lehmann e,f, Serge Van Calenbergh a,

⇑

a Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
b Medicinal Chemistry (Rega Institute), Department of Pharmaceutical and Pharmacological Sciences, KU LEUVEN, Minderbroedersstraat 10 blok x-box 1030, 3000 Leuven, Belgium
c Laboratory for Organic and Bioorganic Synthesis, Department of Pharmaceutical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Antwerpen, Belgium
d Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Department of Pharmaceutical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Antwerpen, Belgium
e Institut Pasteur, Unit of Chemistry and Biocatalysis, Department of Structural Biology and Chemistry, 28 Rue du Dr. Roux, 75724 Paris Cedex 15, France
f CNRS UMR3523, Paris, France

An error is present on page 5175 of the above mentioned published paper. Since we were unable to reproduce the in vitro activity of compound 5 against M. tuberculosis, the final sentence of the second paragraph, Section 2.2 should read as follows:

However, Compound 5 was found to be inactive against an Mtb H37Ra strain (IC_{50}>64\mu M).

The authors would like to apologize for any inconvenience caused.